Les informations fournies sur EL7.AI sont uniquement à des fins éducatives et informatives et ne constituent pas un conseil financier.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

ActionsMoyen•30 March 2026•

1 min de lecture

Palisade Bio Reports Positive Phase 1b Results for Crohn's Disease Treatment

Faits marquants

1PALI-2108 demonstrated a 47.5% reduction in SES-CD score, indicating significant endoscopic improvement.

240% of patients in the study achieved endoscopic response and remission after two weeks of treatment.

3The company plans to advance PALI-2108 into Phase 2 trials for moderate to severe Crohn's disease.

Inscrivez-vous gratuitement pour accéder à ce contenu

Créer un compte gratuit

Historique des versions

2 sources supplémentaires ont confirmé cette actualité

Palisade Bio (Nasdaq: PALI) announced positive topline results from its Phase 1b study of PALI-2108, an oral PDE4 inhibitor targeting Crohn's disease. The study demonstrated significant clinical activity, with the drug showing a 47.5% reduction in the SES-CD score, a key indicator of endoscopic improvement. Notably, 40% of the participating patients achieved both endoscopic response and remission within just two weeks of treatment. The trial successfully met its primary endpoints for safety and tolerability, providing a strong foundation for further clinical development. Following these favorable results, the company plans to advance PALI-2108 into Phase 2 clinical trials for patients with moderate to severe Crohn's disease. This development marks a significant milestone for the biotech firm as it seeks to address unmet needs in fibrostenotic Crohn's disease.